{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:33Z","timestamp":1790706153947,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Obesity is a growing public health concern associated with increased risk of chronic diseases, including type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become a key therapeutic option for obesity management, yet real-world evidence describing short-term changes in body composition, particularly with newer agents such as tirzepatide, remains limited. This retrospective study examined changes in body weight, body mass index (BMI), and body composition among adults with obesity receiving GLP-1 receptor agonist therapy within a clinical obesity medicine program that included individualized lifestyle guidance. Thirty-five adults (53.4 \u00b1 7.8 years; BMI 37.2 \u00b1 9.16 kg\/m\u00b2) receiving tirzepatide were evaluated. Therapy was initiated at 2.5 mg or 5 mg once weekly, with scaffolded dose escalation up to 15 mg based on tolerance and clinical response. Body weight was measured using standard procedures, and body composition was assessed with bioelectrical impedance analysis (InBody770) at baseline and follow-up visits. Linear mixed models and ANOVA were used to examine effects of time, sex, and baseline weight status (p &amp;lt; 0.050).GLP-1RA therapy resulted in significant reductions in body weight (\u221231.1 kg; \u221227.8%), BMI (\u221210.4 kg\/m\u00b2; \u221227.8%), body fat percentage (\u221216.2%; \u221237.6%), fat mass (\u221226.4 kg; \u221254.2%), fat-free mass (\u22124.5 kg; \u22127.3%), skeletal muscle mass (\u22122.8 kg; \u22128.3%), and total body water (\u22123.5 kg; \u22127.7%) (all p &amp;lt; 0.001). Weight loss was predominantly attributable to fat mass, comprising 85.7% (95% CI: 81.9, 89.5) of total weight loss, with smaller contributions from fat-free and skeletal muscle mass. Reductions in extracellular (\u22122.6 kg; \u22129.5%) and intracellular water (\u22121.3 kg; \u22127.4%) were observed; however, fluid distribution indices did not change significantly over time.Sex-specific analyses showed females experienced greater percentage reductions in fat mass, fat-free mass, skeletal muscle mass, and total body water compared to males, while males exhibited greater reductions in fluid ratios (p &amp;lt; 0.05). Participants with higher baseline BMI demonstrated significantly greater percentage reductions in weight, BMI, fat mass, and body fat percentage compared to those with lower baseline BMI (p &amp;lt; 0.05), although post-treatment values were not significantly different between groups.<\/jats:p>","DOI":"10.3389\/fendo.2026.1834580","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:52:56Z","timestamp":1783486376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity"],"prefix":"10.3389","volume":"17","author":[{"given":"Haley","family":"Corso","sequence":"first","affiliation":[{"name":"Department of Kinesiology, Coastal Carolina University","place":["Conway, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin J.","family":"Graybeal","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Harris College of Nursing and Health Sciences, Texas Christian University","place":["Fort Worth, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hoelscher","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Coastal Carolina University","place":["Conway, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Roberson","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Coastal Carolina University","place":["Conway, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Coastal Carolina University","place":["Conway, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Johnson","sequence":"additional","affiliation":[{"name":"Precision Medical Care LLC","place":["Clarendon Hills, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Coastal Carolina University","place":["Conway, SC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60460-8","article-title":"Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"384","author":"Ng","year":"2014","journal-title":"Lancet"},{"key":"B2","volume-title":"Obesity and Overweight","year":"2024"},{"key":"B3","article-title":"Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors---United States","volume":"60","year":"2011","journal-title":"MMWR: Morbidity Mortality Weekly Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1201\/9781003437734-3","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/dom.14200","article-title":"Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-865-x:209","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.clnu.2012.06.010","article-title":"Sarcopenic obesity: A critical appraisal of the current evidence","volume":"31","author":"Prado","year":"2012","journal-title":"Clin Nutr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13090","DOI":"10.1038\/s41598-023-40366-4","article-title":"Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome","volume":"13","author":"Freitas","year":"2023","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease: An update","volume":"126","author":"Despr\u00e9s","year":"2012","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-026-02088-1","article-title":"GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis","author":"Sawicka-Gutaj","year":"2026","journal-title":"Int J Obes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.07.041","article-title":"Skeletal muscle and fat-free mass: related but distinct concepts in body composition","volume":"122","author":"Tinsley","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7570\/jomes25010","article-title":"The Critical Role of Body Composition Assessment in Advancing Research and Clinical Health Risk Assessment across the Lifespan","volume":"34","author":"Bennett","year":"2025","journal-title":"J. Obesity & Metabolic Syndrome"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1834580\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:52:59Z","timestamp":1783486379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1834580\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":21,"alternative-id":["10.3389\/fendo.2026.1834580"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1834580","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1834580"}}